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MICROABSTRACT 
Reactivation of latent human herpesvirus-6 (HHV6) can be associated with prolonged 
pancytopenia following allogeneic hematopoietic cell transplantation (HCT). Reports of HHV6 
complications in autologous HCT is limited. This case report describes HHV6 reactivation 
complicated by atypical lymphocytosis of characteristic CD4+/CD8+ cells and subsequent 
prolonged pancytopenia after autologous peripheral blood stem cell transplantation (PBSCT) for 
multiple myeloma (MM). 
 
ABSTRACT 
Introduction: 
Reactivation of latent human herpesvirus 6 (HHV-6) often occurs after hematopoietic cell 
transplantation (HCT). Following autologous HCT, HHV-6 reactivation has been associated with 
a slight delay in hematopoietic recovery, however, it has not been associated acute alterations in 
peripheral leukocytes.  
Case Report: 
In this report, we describe prolonged pancytopenia as a consequence of HHV-6 reactivation in a 
63-year-old man who underwent autologous peripheral blood stem cell transplantation (PBSCT) 
for multiple myeloma. Preceding this pancytopenia, there was a transient atypical lymphocytosis 
consisting of double positive CD4+/CD8+ T-lymphocytes.  
Results: 
Flow cytometry of peripheral blood on day +11 showed atypical lymphocytes positive for CD4 
and CD8. Quantitative PCR was positive for HHV6 with 250 copies/mL and negative for CMV 
and EBV. Bone marrow aspirate and biopsy on day +31 showed marked erythroid hyperplasia 
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(M:E ratio 0.18) and a small population (1.7%) of T-cells coexpressing CD4 and CD8. On day 
+38, the ANC was 0.99 x 106/L. 
Conclusion: 
This instructive case demonstrates that HHV6 reactivation after autologous PBSCT can be 
associated with atypical lymphocytosis of characteristic CD4+/CD8+ cells and subsequent 
prolonged pancytopenia. HHV6 is known to induce expression of CD4 in CD8+ lymphocytes, 
and that viral reactivation likely led to the observed CD4+/CD8+ lymphocytosis. As autologous 
HCT remains a component of MM comprehensive therapy, transplant infectious diseases 
specialists and HCT physicians are encouraged to have a low index of suspicion for HHV6 
reactivation when assessing MM patients who develop persistent fevers, rashes, atypical 
lymphocytosis or prolonged marrow hypoplasia after autologous HCT. 
 
Keywords: human herpesvirus 6, CD4+/CD8+ lymphocytes, autologous peripheral blood stem 
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INTRODUCTION 
 Reactivation of latent human herpesvirus 6 (HHV-6) is common after allogeneic 
hematopoietic cell transplantation (HCT; transplantation of bone marrow, peripheral blood stem 
cells, or cord blood), occurring in approximately 40-70% of those recipients1,2. After autologous 
HSCT, the reported incidence of HHV-6 reactivation is either similar to1,2,3 or lower than (8-
19%) that observed after allogeneic HCT4,5,6,7. Much of the literature agrees there is no 
statistically significant difference between HHV-6 reactivation in autologous and allogeneic 
recipients1,2,5,8,9. Manifestations of HHV-6 reactivation following either autologous or allogeneic 
HCT may include fever and rash2,10; after autologous HCT, diarrhea and pneumonitis may also 
occur4. Reactivation of this virus often occurs during pancytopenia and thus is not associated 
with acute elevations or alterations in peripheral blood leukocytes, potentially informative 
diagnostic findings that can be observed with HHV-6 infection in normal individuals11,12. 
 Previous literature reports at most a modest delay in hematological recovery following 
active HHV-6 infection for both allogeneic and autologous HCT, with a median duration of 
neutropenia of 12.5 days (range, 6-21 days)2. However, this does not drastically differ from 
neutrophil aplasia experienced by patients undergoing their first autologous PBSCT, where the 
median time to neutrophil engraftment was 12 days (range, 9-25 days)13. Extremely prolonged 
pancytopenia and graft failure associated with HHV-6 reactivation are well-recognized after 
allogeneic HCT14,15, but to our knowledge have not been extensively reported after autologous 
HCT. 
In this report, we describe a transient atypical lymphocytosis with CD4+/CD8+ cells 
followed by prolonged bone marrow hypoplasia as manifestations of HHV-6 reactivation in a 
patient who underwent autologous peripheral blood stem cell transplantation (PBSCT) for 
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multiple myeloma. The CD4+/CD8+ immunophenotypic profile is historically associated with 
intrathymic T cell development. However, circulating double positive T-lymphocytes can be 
found in healthy individuals and has been linked to an adaptive immune response to various 
pathogens16. Additionally, previous literature has linked HHV-6 to the induction of CD4 
expression in CD8+ lymphocytes17. 
 
CASE REPORT 
A 63-year-old man was diagnosed with IgA kappa multiple myeloma (Durie-Salmon 
Stage IIIA and ISS stage 3). He received initial treatment with lenalidomide, bortezomib, and 
dexamethasone; pomalidomide replaced lenalidomide for subsequent cycles because of 
intolerance to lenalidomide. Following this treatment, the patient’s myeloma attained a first 
complete response, and he proceeded to autologous PBSCT. Pre-transplant evaluation included 
positive immunoglobulin G (IgG) antibodies against herpes simplex virus (8.64 IV) and HHV-6 
(titer 1:320), consistent with latent infections, and negative IgG against cytomegalovirus and 
human immunodeficiency virus. Although the patient reported varicella infection in childhood, 
varicella-zoster IgG was negative. After collection of peripheral blood stem cells that were 
mobilized with granulocyte colony-stimulating factor (G-CSF) and plerixafor, the patient 
underwent autologous PBSCT following a preparative regimen of high-dose intravenous 
melphalan (200 mg/m2); CD34+ cell dose was 10.94 x 106/kg. He received prophylactic 
acyclovir, ciprofloxacin, and fluconazole post-transplant. 
On the first day post-transplant (day +1), he was febrile to 38.9°C and began empiric 
treatment with cefepime. Fever resolved, and bacterial cultures of blood and urine remained 
negative. On day +6, the patient had rigors and recurrence of fever to 40°C; at that time, he was 
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pancytopenic with a white blood cell (WBC) count of less than 0.1 x 109/L. Empiric vancomycin 
was added, and cefepime was continued. By day +7, fevers, rigors, and pancytopenia persisted, 
and the patient developed dyspnea, tachycardia, diarrhea, hypotension, and a diffuse 
erythematous macular and papular rash. Repeat bacterial cultures of blood and urine, a multiplex 
viral respiratory panel, and assay of stool for Clostridium difficile toxin were all negative. On 
day +9, the patient continued to have fever and rash and sustained a cardiac arrest, for which he 
required intubation and several days of pressor support with phenylephrine, vasopressin, and 
norepinephrine. On day +11, a skin biopsy showed both interface and spongiotic dermatitis with 
some eosinophils and extravasated red cells, without dyskeratotic cells or vasculitis. Therefore, 
skin biopsy was not consistent with typical findings of drug reaction or graft-versus-host disease. 
Peripheral blood studies at that time showed the WBC count was 11.2 x 109/L, of which 
approximately 60% were atypical lymphocytes (Figure 1); the absolute neutrophil count (ANC) 
was zero. Flow cytometry showed that these lymphocytes were positive for both CD4 and CD8 
(Figure 2). Quantitative PCR for CMV and for Epstein-Barr virus DNA were negative. However, 
on day +11, a quantitative PCR for HHV-6 DNA was 250 copies/mL. 
By day +14, both fever and rash had resolved. The abrupt and precipitous atypical 
lymphocytosis was then followed by prolonged pancytopenia (Figure 3). By day +30, the 
absence of WBC or ANC recovery was of concern for primary graft failure. A bone marrow 
aspirate and biopsy on day +31 showed 80-90% cellularity with marked erythroid hyperplasia 
(M:E ratio 0.18) and a small population (1.7%) of T-cells coexpressing CD4 and CD8. On day 
+34, the patient received a second autologous PBSC infusion (CD34+ cell dose, 10.94 x 106/kg). 
By day +38 (four days after the second PBSC infusion), the ANC was 0.99 x 106/L. 
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On day +34, the patient was extubated. He had several other comorbidities and 
complications including deconditioning, poor caloric intake, and intermittent atrial fibrillation. 
On day +54, he was discharged from the hospital. Evaluation at day +94 showed complete 
response of myeloma, with no monoclonal proteins, normal free light chain ratio, and negative 
serum and urine immunofixation. 
 
DISCUSSION 
We believe that this report is instructive because of the occurrence of both atypical 
lymphocytosis with CD4+/CD8+ cells and prolonged pancytopenia associated with HHV-6 
reactivation after autologous HCT. In immunocompetent patients, infection with HHV-6 can 
present with mononucleosis-like manifestations, including absolute and atypical 
lymphocytosis11,12. However, these peripheral blood findings have not previously been observed 
in allogeneic or autologous HCT recipients who develop HHV-6 reactivation, whether during 
post-transplant pancytopenia or following hematopoietic engraftment recovery. The onset of 
HHV-6 viremia correlates with lymphocyte and monocyte recovery following allogeneic HCT, 
albeit at low levels of those cells (0.05 x 109/L)18; in contrast, we observed an ALC that was 
almost 100 times that level. The development of absolute and atypical lymphocytosis in our 
patient was concomitant with persistent fevers, rash, and positive quantitative HHV-6 DNA by 
PCR. The viral load in this patient was comparable to that reported in allogeneic HCT recipients 
with HHV-6 reactivation (median, 138 copies/mL)10. The immunophenotypic profile of the 
atypical lymphocytes showed coexpression of CD4 and CD8, a population of lymphocytes that is 
generally confined to the thymus during T-cell maturation. However, these cells can also be 
found sparingly in the peripheral circulation of healthy individuals16. Although the exact purpose 
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of these circulating double positive T-lymphocytes is unknown, it is believed that they play a 
role in fighting viral infections16. Additionally, HHV-6 has been reported to induce expression of 
CD4 in peripheral CD8+ lymphocytes through de novo expression of CD4 messenger RNA and 
subsequent glycoprotein17, therefore, it is likely that viral reactivation led to atypical 
lymphocytosis with this characteristic immunophenotype. 
Previous reports have indicated either no or minimal (1-3 day) delay in neutrophil 
engraftment after autologous PBSCT in patients with HHV-6 reactivation compared with those 
in whom viral reactivation did not occur1,2,19. In our case, neutrophil recovery did not occur until 
38 days after first PBSCT. Extreme delay in neutrophil recovery after autologous PBSCT is 
decidedly uncommon; in 397 patients undergoing first autologous PBSCT, median time to 
neutrophil engraftment was 12 days (range, 9 to 25 days)13. Although the patient received a 
second infusion of autologous PBSCs at day +34 because of concern for primary graft failure, 
the recovery of neutrophils just four days later strongly indicates that the initial transplant was 
responsible for hematopoietic recovery. Additionally, our patient had prolonged 
thrombocytopenia; only at 47 days post-transplant did the platelet levels exceed 50 x 109/L 
without transfusion. In contrast, the median time to platelet engraftment after autologous PBSCT 
was 15 days (range, 10 to 27 days)13. 
Several in vitro studies have confirmed the inhibitory effects of HHV-6 on 
hematopoiesis. For example, exposure to HHV-6 prevented cytokine-induced maturation of 
marrow-derived macrophage progenitors by approximately 90%20. Another study showed that 
HHV-6 not only negatively affected proliferation but also inhibited differentiation of marrow 
stromal cells, pluripotent stem cells, erythroid precursors and granulocyte/macrophage 
precursors21. The myelosuppression is mediated by production of viral-associated factors that 
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interfere with the responsiveness of hematopoietic progenitors to growth factors, and not directly 
by active HHV-6 replication20. 
 It is important to note that there are two distinct variations of HHV-6: HHV-6A and 
HHV-6B. These variants share about 88% sequence homology and are morphologically similar, 
yet their biological, epidemiological and clinical differences have led to their recognition as two 
distinct viruses by the International Committee for Taxonomy of Viruses in 201222,23,24. Both 
HHV-6 variants target the CD46 receptor and preferentially replicate in CD4+ cells25. However, 
HHV-6A tends to more efficiently target the different types of cytotoxic effector cells compared 
to its more restricted variant, HHV-6B17. HHV-6A has also been specifically linked to the 
induction of CD4 expression in CD8+ T cells17. In vitro studies have suggested that the variants 
of HHV-6 may have differential effects on hematopoiesis, with more inhibitory effects observed 
with HHV-6B than with HHV-6A26. Unfortunately, we were not able to identify the specific 
HHV-6 variant that became reactivated in our patient. 
The determinants of HHV-6 reactivation after autologous HCT are not clear. Our patient 
had received the proteasome inhibitor bortezomib, the use of which is associated with increased 
risks of reactivation of other latent herpesviruses, including herpes simplex and herpes zoster27. 
That previous bortezomib treatment may increase the risk of HHV-6 reactivation after 
autologous HCT for myeloma is supported by a recent study that showed almost a twofold 
greater incidence of post-transplant HHV-6 reactivation in patients who had received bortezomib 
plus dexamethasone when compared with those who received thalidomide plus dexamethasone 
(19.5% versus 9.5%, respectively)7. 
Current treatment recommendations for newly-diagnosed myeloma include bortezomib, 
usually combined with lenalidomide and dexamethasone28. Additionally, autologous HCT is a 
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preferred component of comprehensive therapy of multiple myeloma, as it provides longer 
progression-free survival than conventional treatment29. In view of these factors, the potential 
association of bortezomib with HHV-6 reactivation, and our and other reports, both the 
transplant infectious diseases specialist and the transplant physician may need to have a lower 
index of suspicion for HHV-6 reactivation when assessing myeloma patients who develop 
persistent fevers, rashes, atypical lymphocytosis, or prolonged marrow hypoplasia after 
autologous PBSCT. 
 
CONCLUSION 
 In conclusion, it is believed that the reactivation of HHV-6 lead to an atypical 
lymphocytosis involving circulating CD4 and CD8 positive lymphocytes, followed by a 
prolonged pancytopenia in a 63-year-old man who underwent autologous PBSCT for multiple 
myeloma. Modest delayed bone marrow engraftment has been associated with HHV-6 
reactivation in prior literature2. However, to our knowledge, atypical circulating lymphocytes 
expressing both CD4 and CD8 have not previously been associated with PBSCT. There is still 
much to learn about HHV-6 reactivation in transplant recipients, however, it is clear that 
physicians must be aware of its association with prolonged marrow hypoplasia after autologous 
PBSCT. 
 
CLINICAL PRACTICE POINTS 
• Reactivation of latent human herpesvirus-6 (HHV6) is often seen after allogeneic 
hematopoietic cell transplantation (HCT). HHV6 reactivation following HCT has been 
associated with a slight delay in hematopoietic recovery. 
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• HHV6 is known to induce expression of CD4 in CD8+ lymphocytes, and that viral 
reactivation likely led to the observed CD4+/CD8+ lymphocytosis. CD4+/CD8+ lymphocytes 
can also be found sparingly in the peripheral circulation of healthy individuals. 
• This instructive case demonstrates that HHV6 reactivation after autologous PBSCT can be 
associated with atypical lymphocytosis of characteristic CD4+/CD8+ cells and subsequent 
prolonged pancytopenia. 
• As autologous HCT remains a component of MM comprehensive therapy, transplant 
infectious diseases specialists and HCT physicians are encouraged to have a low index of 
suspicion for HHV6 reactivation when assessing MM patients who develop persistent fevers, 
rashes, atypical lymphocytosis or prolonged marrow hypoplasia after autologous HCT. 
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FIGURE CAPTIONS 
 
Figure 1. Photomicrograph of Wright-Giemsa stained peripheral blood smear obtained at day 
+11 post-transplant, showing large atypical lymphoid cells with moderately-abundant deeply 
basophilic cytoplasm, irregular nuclear contours and condensed nuclear chromatin (100x). 
 
Figure 2. Flow cytometric analysis of peripheral blood at day +11 post-transplant, showing the 
lymphocytes (green) to represent 92% of total events. The majority of the lymphocytes are CD3+ 
T-cells with a subset showing coexpression of CD4 and CD8 (20% of all lymphocytes). The 
events (pink) represent a significant number of red blood cells and cellular debris. 
 
Figure 3. Levels of white blood cells, absolute neutrophils, absolute lymphocytes, and absolute 
atypical lymphocytes following autologous PBSCT for multiple myeloma.  
 
  
Figure 1 
 
  
 Figure 2 
 
  
 Figure 3 
 
 
